EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of chronic trypanosomiasis on the bioavailability of alpha -difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay






Parasitology Research 83(4): 386-389

Effect of chronic trypanosomiasis on the bioavailability of alpha -difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay

A method for detecting alpha -difluoromethylornithine (DFMO) in plasma during pharmacokinetic studies in mice is described, using conventional reversed-phase HPLC with UV detection. It was shown that mice infected with Trypanosoma brucei had Cmax values 2-fold higher than those of non-infected mice. It is concluded that pharmacokinetic studies should compare both infected and naive subjects.


Accession: 002811061

PMID: 9134564



Related references

Loiseau, P.M.; Chauffert, O.; Czok, M., 1997: Effect of chronic trypanosomiasis on the bioavailability of alpha-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay. A method for detecting alpha -difluoromethylornithine (DFMO) in plasma during pharmacokinetic studies in mice is described, using conventional reversed-phase HPLC with UV detection. It was shown that mice infected with Trypanosoma brucei had Cmax...

Arakali A.V.; Pendyala L.; Hensen M.L.; Murphy M.J.; Porter C.; Creaven P.J., 1990: Pharmacokinetics pk of alpha difluoromethylornithine dfmo and levels of polyamines in patients pts receiving dfmo in a phase i chemoprevention study. Proceedings of the American Association for Cancer Research Annual Meeting 31: 182

Loiseau, P.M.; Czok, M.; Chauffert, O.; Bourass, J.; Letourneux, Y., 1998: Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model. DFMO, a trypanostatic drug, presents a satisfactory intestinal absorption but its elimination from the blood is rapid so that high doses are necessary to obtain to therapeutic effect. In this study, we propose a strategy to enhance the bioavailabi...

Loiseau, P.M.; Czok, M.; Chauffert, O.; Bourass, J.; Letourneux, Y., 1998: Studies on lipidomimetic derivatives of alpha -difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma b. brucei murine trypanosomiasis model. Three lipidomimetic alpha -difluoromethylornithine (DFMO, eflornithine) derivatives (designated O-DFMO, S-DFMO and Chol-DFMO) were designed to easily reach the plasma and to be cleaved preferentially by plasma esterases, progressively liberating f...

Nie, L.; Feng, W.; Diaz, R.; Gratton, M.A.; Doyle, K.Jo.; Yamoah, E.N., 2005: Functional consequences of polyamine synthesis inhibition by L-alpha-difluoromethylornithine (DFMO): cellular mechanisms for DFMO-mediated ototoxicity. L-Alpha-difluoromethylornithine (DFMO) is a chemopreventive agent for colon cancer in clinical trials. Yet, the drug produces an across-frequency elevation of the hearing threshold, suggesting that DFMO may affect a common trait along the cochlear...

Nie, L.; Feng, W.; Diaz, R.; Gratton, M., A.; Doyle, K.-Jo; Yamoah, E., N., 2005: Functional consequences of polyamine synthesis inhibition by L-alpha- difluoromethylornithine (DFMO) - Cellular mechanisms for DFMO-mediated ototoxicity. L-alpha-Difluoromethylornithine (DFMO) is a chemopreventive agent for colon cancer in clinical trials. Yet, the drug produces an across-frequency elevation of the hearing threshold, suggesting that DFMO may affect a common trait along the cochlear...

Umemoto, S., 1989: Antitumor effect of alpha-difluoromethylornithine (DFMO) changes in ornithine decarboxylase (ODC) activity and polyamine (PA) levels in human tumor transplanted into nude mice. Three human carcinoma xenografts serially transplanted into nude mice were used for the study of antitumor effect of DFMO. One breast carcinoma (MX-1) and two colon carcinomas (Exp-42, Co-3) were inoculated into the subcutaneous tissue of BALB/c n...

Jennings, F.W., 1992: Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL- alpha -difluoromethylornithine (DFMO). The chemotherapy of CNS-trypanosomiasis with DL- alpha -difluoromethylornithine (Eflornithine, DFMO) combined with the diamidine, pentamidine (Lomidine) or diminazene aceturate (Berenil) was examined using the mouse model for CNS-trypanosomiasis....

Jennings, F.W., 1992: Chemotherapy of CNS-trypanosomiasis: the combined use of diminazene aceturate or pentamidine with DL-alpha-difluoromethylornithine (DFMO). The chemotherapy of CNS-trypanosomiasis with DL-alpha-difluoromethylornithine (Eflornithine, DFMO) with the diamidine, pentamidine (Lomidine) or diminazene aceturate (Berenil) was examined using the mouse model for CNS-trypanosomiasis. Although co...

Eze, M.O., 1991: Towards more efficacious chemotherapy of trypanosomiasis: combination of alpha-difluoromethylornithine (DFMO) with reactive oxygen generating drugs. Trypanosomiasis (whether African sleeping sickness, or American Chaga's disease) is caused by an infection with a protozoan parasite, i.e. the trypanosome. This carries fatal sequences in the untreated host. Currently available chemotherapeut...